Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Conagra Brands Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while Conagra Brands Inc trades at $14.77 (market cap $7.14B). The key difference: Conagra Brands Inc is the larger of the two by market cap, and Conagra Brands Inc pays a 8.2% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CAG | |
|---|---|---|
Market Cap | $5.07B | $7.14B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $20.02 |
52-Week Low | $20.06 | $12.58 |
Enterprise Value | $4.19B | $14.20B |
Dividend Yield | — | 8.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Conagra Brands (CAG) trades at $14.78, down 2.18% today, with a bearish technical signal and neutral oscillators. The company reported a net income margin of -16.99% for 2026, with revenue declining to $11.3B, while 2025 showed stronger profitability. Recent corporate actions include a dividend cut to $0.18 and leadership changes under CEO John Brase, aiming to streamline operations and reduce debt.
The outlook is mixed: low valuation metrics (P/E 10.06, P/S 0.63) offer downside support, but weak growth and margin pressures pose risks. Analyst consensus is cautious with a $13.67 price target, and institutional sentiment is divided amid ongoing turnaround efforts. Key risks include consumer pushback on pricing and execution challenges under new management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
